Jupiter Asset Management Ltd. Reduces Stake in Envista Holdings Co. (NYSE:NVST)

Jupiter Asset Management Ltd. cut its holdings in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 71.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,149,694 shares of the company's stock after selling 2,918,569 shares during the period. Jupiter Asset Management Ltd. owned 0.67% of Envista worth $22,178,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NVST. Pzena Investment Management LLC purchased a new position in Envista during the 4th quarter valued at $16,979,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Envista by 17.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,057 shares of the company's stock worth $811,000 after buying an additional 6,320 shares during the period. Raymond James Financial Inc. bought a new stake in Envista during the 4th quarter valued at approximately $10,808,000. Proficio Capital Partners LLC purchased a new position in shares of Envista during the 4th quarter worth approximately $358,000. Finally, M&T Bank Corp raised its position in shares of Envista by 4.2% in the 4th quarter. M&T Bank Corp now owns 16,621 shares of the company's stock worth $320,000 after acquiring an additional 676 shares in the last quarter.

Wall Street Analysts Forecast Growth

NVST has been the topic of several recent research reports. Morgan Stanley reduced their price target on Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. UBS Group lowered their price objective on Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Monday. JPMorgan Chase & Co. cut their target price on Envista from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a research report on Thursday, March 6th. Finally, Jefferies Financial Group increased their price objective on shares of Envista from $20.00 to $22.00 and gave the company a "hold" rating in a research report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Envista presently has an average rating of "Hold" and an average target price of $20.18.

Remove Ads

Envista Stock Down 2.4 %

NVST opened at $16.73 on Thursday. The stock has a market capitalization of $2.88 billion, a price-to-earnings ratio of -2.58, a PEG ratio of 1.27 and a beta of 1.33. The firm has a 50 day moving average price of $20.10 and a 200-day moving average price of $19.67. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.